IgA vasculitis with underlying monoclonal IgA gammopathy: innovative therapeutic approach targeting plasma cells. A case series.

Antoine HankardSaskia Ingen-Housz-OroKhalil El KarouiRomain PauleBertrand LiogerBenoit BrihayeMaxime BattistellaStéphanie JobardJulie MagnantElisabeth DiotAdrien BigotNicole Ferreira-MaldentSophie DeriazAnn-Rose CookHélène HeniqueFrancois MaillotAchille AoubaAlexandra Audemard-Vergernull null

Published in: Clinical rheumatology (2022)

This study suggests that the MG-IgAV phenotype might be distinctive of usual IgAV (severe and refractory to conventional immunosuppressive regimens) and supports the benefit of PCTT. This study sheds new light on the overall biology of IgAV, strengthening the pathogenic role of the monoclonal IgA component in IgAV.

Keyphrases

induced apoptosis
multiple myeloma
drug delivery
early onset
cancer therapy